ZA9810743B - Inhibition of lipoprotein oxidation - Google Patents
Inhibition of lipoprotein oxidationInfo
- Publication number
- ZA9810743B ZA9810743B ZA9810743A ZA9810743A ZA9810743B ZA 9810743 B ZA9810743 B ZA 9810743B ZA 9810743 A ZA9810743 A ZA 9810743A ZA 9810743 A ZA9810743 A ZA 9810743A ZA 9810743 B ZA9810743 B ZA 9810743B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibition
- lipoprotein oxidation
- lipoprotein
- oxidation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6688897P | 1997-11-25 | 1997-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9810743B true ZA9810743B (en) | 1999-05-31 |
Family
ID=22072341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9810743A ZA9810743B (en) | 1997-11-25 | 1998-11-24 | Inhibition of lipoprotein oxidation |
Country Status (23)
Country | Link |
---|---|
US (1) | US6362236B1 (fr) |
EP (1) | EP1047421A2 (fr) |
JP (1) | JP2001523694A (fr) |
KR (3) | KR100539644B1 (fr) |
CN (1) | CN1160068C (fr) |
AR (1) | AR015487A1 (fr) |
AU (1) | AU759376B2 (fr) |
BR (1) | BR9815039A (fr) |
CA (1) | CA2303864A1 (fr) |
CO (1) | CO4970835A1 (fr) |
HK (1) | HK1033095A1 (fr) |
HU (1) | HUP0004396A3 (fr) |
IL (1) | IL135154A (fr) |
IS (1) | IS5413A (fr) |
NO (1) | NO20002639D0 (fr) |
NZ (1) | NZ503598A (fr) |
PE (1) | PE134199A1 (fr) |
PL (1) | PL341397A1 (fr) |
TR (1) | TR200001522T2 (fr) |
TW (1) | TW552137B (fr) |
UY (1) | UY25268A1 (fr) |
WO (1) | WO1999026583A2 (fr) |
ZA (1) | ZA9810743B (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
US7250304B2 (en) * | 2000-03-31 | 2007-07-31 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
PT2404890T (pt) | 2003-01-23 | 2017-10-23 | Esperion Therapeutics Inc | Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas |
US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
WO2006104399A1 (fr) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Compositions antagonistes du cuivre |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
WO2010127103A1 (fr) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Composition pharmaceutique stable et ses procédés d'utilisation |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) * | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (fr) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (fr) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
KR101665180B1 (ko) | 2014-07-01 | 2016-10-14 | 순천향대학교 산학협력단 | 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물 |
JP6940411B2 (ja) | 2015-03-13 | 2021-09-29 | エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. | Etc1002及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 |
MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (fr) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
CN112437765A (zh) | 2019-06-21 | 2021-03-02 | 艾斯柏伦治疗公司 | 贝派地酸的盐形式及其使用方法 |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
-
1998
- 1998-11-04 TR TR2000/01522T patent/TR200001522T2/xx unknown
- 1998-11-04 BR BR9815039-1A patent/BR9815039A/pt not_active Application Discontinuation
- 1998-11-04 HU HU0004396A patent/HUP0004396A3/hu unknown
- 1998-11-04 EP EP98959378A patent/EP1047421A2/fr not_active Withdrawn
- 1998-11-04 KR KR10-2000-7005641A patent/KR100539644B1/ko not_active IP Right Cessation
- 1998-11-04 IL IL13515498A patent/IL135154A/xx not_active IP Right Cessation
- 1998-11-04 CN CNB988112671A patent/CN1160068C/zh not_active Expired - Fee Related
- 1998-11-04 KR KR1020057021847A patent/KR100586754B1/ko not_active IP Right Cessation
- 1998-11-04 US US09/485,250 patent/US6362236B1/en not_active Expired - Fee Related
- 1998-11-04 KR KR1020057014824A patent/KR20050086975A/ko not_active Application Discontinuation
- 1998-11-04 PL PL98341397A patent/PL341397A1/xx not_active Application Discontinuation
- 1998-11-04 JP JP2000521788A patent/JP2001523694A/ja not_active Abandoned
- 1998-11-04 WO PCT/US1998/023483 patent/WO1999026583A2/fr not_active Application Discontinuation
- 1998-11-04 AU AU15188/99A patent/AU759376B2/en not_active Ceased
- 1998-11-04 CA CA002303864A patent/CA2303864A1/fr not_active Abandoned
- 1998-11-04 NZ NZ503598A patent/NZ503598A/en unknown
- 1998-11-24 UY UY25268A patent/UY25268A1/es not_active Application Discontinuation
- 1998-11-24 ZA ZA9810743A patent/ZA9810743B/xx unknown
- 1998-11-24 AR ARP980105959A patent/AR015487A1/es unknown
- 1998-11-24 PE PE1998001143A patent/PE134199A1/es not_active Application Discontinuation
- 1998-11-24 CO CO98069227A patent/CO4970835A1/es unknown
- 1998-11-25 TW TW087119590A patent/TW552137B/zh not_active IP Right Cessation
-
2000
- 2000-03-24 IS IS5413A patent/IS5413A/is unknown
- 2000-05-23 NO NO20002639A patent/NO20002639D0/no unknown
-
2001
- 2001-06-04 HK HK01103822A patent/HK1033095A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CO4970835A1 (es) | 2000-11-07 |
UY25268A1 (es) | 1999-07-19 |
JP2001523694A (ja) | 2001-11-27 |
AU1518899A (en) | 1999-06-15 |
IL135154A (en) | 2005-05-17 |
EP1047421A2 (fr) | 2000-11-02 |
KR20050086975A (ko) | 2005-08-30 |
WO1999026583A2 (fr) | 1999-06-03 |
AR015487A1 (es) | 2001-05-02 |
NO20002639L (no) | 2000-05-23 |
BR9815039A (pt) | 2001-03-20 |
KR20050113288A (ko) | 2005-12-01 |
PL341397A1 (en) | 2001-04-09 |
WO1999026583A3 (fr) | 1999-12-09 |
IL135154A0 (en) | 2001-05-20 |
CA2303864A1 (fr) | 1999-06-03 |
KR20010032401A (ko) | 2001-04-16 |
NZ503598A (en) | 2002-06-28 |
HK1033095A1 (en) | 2001-08-17 |
AU759376B2 (en) | 2003-04-10 |
HUP0004396A3 (en) | 2003-04-28 |
TR200001522T2 (tr) | 2000-12-21 |
PE134199A1 (es) | 2000-01-20 |
KR100586754B1 (ko) | 2006-06-08 |
US6362236B1 (en) | 2002-03-26 |
KR100539644B1 (ko) | 2005-12-29 |
CN1279605A (zh) | 2001-01-10 |
CN1160068C (zh) | 2004-08-04 |
TW552137B (en) | 2003-09-11 |
HUP0004396A2 (hu) | 2001-06-28 |
NO20002639D0 (no) | 2000-05-23 |
IS5413A (is) | 2000-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL135154A0 (en) | Inhibition of lipoprotein oxidation | |
PL339551A1 (en) | Derivatives of rezorcin | |
PL334846A1 (en) | Sulphamidic inhibitors of metaloproteases | |
PL337827A1 (en) | Bactericidal derivatives of n-sulphoglycin alkynyloxyphenethylamide | |
PL347029A1 (en) | Reduction of oxidative stress factors | |
SG71785A1 (en) | Deploymerization of polyamides | |
EP1039914A4 (fr) | . inhibition de la cyclooxygenase-2 | |
HU9702480D0 (en) | New polymorphe modification of doxazosin-mesylate | |
PL334769A1 (en) | Derivatives of 5-aroylnaphtene | |
HU9702479D0 (en) | New polymorphe modification of doxazosin-mesylate | |
AU5200699A (en) | Inhibition of lipoprotein formation | |
EP0981545A4 (fr) | Traitement de l'osteoporose | |
PL338777A1 (en) | Derivative of piperidinylmethyloxazolydinone | |
ZA985064B (en) | Derivatives of pentaerythrits | |
GB9706285D0 (en) | Means of assembly | |
PL317319A1 (en) | Oxidative amonolysis of alkylopyridines | |
PL334066A1 (en) | Oily composition of dihydropolyprenoles | |
PL325816A1 (en) | Novel derivatives of naphtylpiperazine | |
IL120955A0 (en) | Treatment of osteoporosis | |
PL313849A1 (en) | Beta-aminoesters of o-hydrobenzylamides | |
PL319263A1 (en) | Novel derivative of pyrimidinylcarbazole | |
PL327430A1 (en) | Set of shaped components | |
TW319017U (en) | Improved structure of mousetraps | |
TW312301U (en) | Improved structure of earmask | |
GB9722026D0 (en) | Use of compounds |